Cardio-Renal-Metabolic
Pipeline

About our Cardio-Renal-Metabolic Diseases efforts

Building on our legacy of innovative treatments for a range of cardiovascular, renal and metabolic conditions, our R&D strategy takes a holistic view of the needs of people with metabolic diseases such as diabetes, who often have multiple, related conditions. We are pursuing the next wave of innovative medicines for obesity, kidney and liver diseases – including metabolic dysfunction-associated steatohepatitis (MASH).

Read more about Survodutide (BI 456906): GLP1/GCGR agonist | obesity

Cardio-Renal-Metabolic

Obesity

GLP1/GCGR agonist

Survodutide (BI 456906)

Read more about Vicadrostat (BI 690517) + empagliflozin

Cardio-Renal-Metabolic

Chronic kidney disease

Aldosterone synthase inhibitor & SGLT2 inhibitor

Vicadrostat (BI 690517) & Empagliflozin

Read more about Vicadrostat (BI 690517) + empagliflozin

Cardio-Renal-Metabolic

Heart failure with preserved ejection fraction

Aldosterone synthase inhibitor & SGLT2 inhibitor

Vicadrostat (BI 690517) & Empagliflozin

Read more about BI 764198: TRPC6 inhibitor

Cardio-Renal-Metabolic

Focal Segmental Glomerulosclerosis

TRPC6 inhibitor

BI 764198

Read more about BI 765845: Heart disease modulator | Myocardial infarction

Cardio-Renal-Metabolic

Myocardial infarction

Heart disease modulator

BI 765845

Read more about Survodutide (BI 456906): GLP1/GCGR agonist | MASH

Cardio-Renal-Metabolic

Metabolic Dysfunction-Associated Steatohepatitis

GLP1/GCGR agonist

Survodutide (BI 456906)

Read more about Anti-fibrotic agent

Cardio-Renal-Metabolic

Anti-fibrotic agent

Read more about GLP-1/FGF21 agonist

Cardio-Renal-Metabolic

GLP-1/FGF21 agonist

Read more about NPY2r agonist

Cardio-Renal-Metabolic

NPY2r agonist

Read more about Triple agonist peptide

Cardio-Renal-Metabolic

Triple agonist peptide